CA2777222A1 - Il-17 family cytokine compositions and uses - Google Patents

Il-17 family cytokine compositions and uses Download PDF

Info

Publication number
CA2777222A1
CA2777222A1 CA2777222A CA2777222A CA2777222A1 CA 2777222 A1 CA2777222 A1 CA 2777222A1 CA 2777222 A CA2777222 A CA 2777222A CA 2777222 A CA2777222 A CA 2777222A CA 2777222 A1 CA2777222 A1 CA 2777222A1
Authority
CA
Canada
Prior art keywords
seq
protein
subunit
numbering
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2777222A
Other languages
English (en)
French (fr)
Inventor
Christopher K. Garcia
Sashank Reddy
Gregory James Sieczkiewicz
Thomas M. Barnes
Michael M. Schmidt
Bracken M. King
Lauren K. Ely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Carisma Therapeutics Inc
Original Assignee
Leland Stanford Junior University
Eleven Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, Eleven Biotherapeutics Inc filed Critical Leland Stanford Junior University
Publication of CA2777222A1 publication Critical patent/CA2777222A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2777222A 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses Abandoned CA2777222A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27877909P 2009-10-10 2009-10-10
US61/278,779 2009-10-10
PCT/US2010/052194 WO2011044563A2 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses

Publications (1)

Publication Number Publication Date
CA2777222A1 true CA2777222A1 (en) 2011-04-14

Family

ID=43857433

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777222A Abandoned CA2777222A1 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses

Country Status (11)

Country Link
US (1) US20130064788A1 (2)
EP (1) EP2485763A4 (2)
JP (1) JP2013507132A (2)
KR (1) KR20120093932A (2)
CN (1) CN102648002A (2)
AU (1) AU2010303166A1 (2)
BR (1) BR112012008444A2 (2)
CA (1) CA2777222A1 (2)
EA (1) EA201270528A1 (2)
IL (1) IL219209A0 (2)
WO (1) WO2011044563A2 (2)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
ES2952394T3 (es) 2010-07-29 2023-10-31 Buzzard Pharmaceuticals AB Antagonistas quiméricos del receptor IL-1 de tipo I
US20140105855A1 (en) * 2011-04-06 2014-04-17 Kenan Christopher Garcia Structural based design of il-17 dominant negative mutants
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
ME03073B (me) 2011-10-19 2019-01-20 Galapagos Nv Ant agonisti il17с za lečenje zapaljenskih poremećaja
EP2768946A1 (en) * 2011-10-21 2014-08-27 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
JP2015521591A (ja) 2012-06-12 2015-07-30 オレガ・バイオテック Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用
EP3417878A1 (en) * 2012-06-12 2018-12-26 Orega Biotech Antagonists of il-17 isoforms and their uses
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
EP2968468B1 (en) 2013-03-13 2021-07-14 Buzzard Pharmaceuticals AB Chimeric cytokine formulations for ocular delivery
CA2909706C (en) * 2013-04-17 2023-02-14 Genzyme Corporation Use of an il17 inhibitor for treating and preventing macular degeneration
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
ES3044918T3 (en) * 2016-03-25 2025-11-27 The Univ Of Osaka Conjugate vaccine targeting disorder-causing in vivo protein
JP2019513775A (ja) * 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
EP3655007A4 (en) * 2017-07-21 2021-04-28 The Cleveland Clinic Foundation SBE APTAMERE FOR THE TREATMENT OF IL-17A DISEASES AND DISEASES
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
PT3946377T (pt) 2019-04-03 2026-03-09 Univ Montpellier Terapias de combinação baseadas em inibidores da pd1 e il-17b
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2021023624A1 (en) * 2019-08-02 2021-02-11 Orega Biotech Novel il-17b antibodies
KR102265435B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2021170750A1 (en) 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2022032592A1 (en) * 2020-08-13 2022-02-17 Tsinghua University Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
CN113403259B (zh) * 2021-06-04 2023-01-17 华南农业大学 一种提高克隆胚胎发育质量的添加剂及其应用
CN113563453A (zh) * 2021-07-23 2021-10-29 四川大学 鸡白细胞介素17b重组乳酸菌免疫制剂的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6569419B2 (en) * 2000-02-29 2003-05-27 Zymogenetics, Inc. Methods for promoting production of myelin by Schwann cells
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
CA2425506A1 (en) * 2000-10-18 2002-08-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
CA2452233A1 (en) * 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2784084B2 (en) * 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20070197441A1 (en) * 2006-02-10 2007-08-23 Rixon Mark W Truncated il-17ra soluble receptor and methods of using in inflammation
EP1996622A2 (en) * 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
EP2046835B1 (en) * 2006-08-11 2011-10-26 Schering Corporation Antibodies to il-17a
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
EP2144928A2 (en) * 2007-04-20 2010-01-20 Amgen Inc. Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor
JP5116842B2 (ja) * 2007-04-27 2013-01-09 ザイモジェネティクス， インコーポレイテッド ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17

Also Published As

Publication number Publication date
EA201270528A1 (ru) 2012-12-28
US20130064788A1 (en) 2013-03-14
IL219209A0 (en) 2012-06-28
WO2011044563A3 (en) 2011-06-03
JP2013507132A (ja) 2013-03-04
EP2485763A4 (en) 2013-10-30
AU2010303166A1 (en) 2012-05-24
EP2485763A2 (en) 2012-08-15
WO2011044563A2 (en) 2011-04-14
BR112012008444A2 (pt) 2019-09-24
CN102648002A (zh) 2012-08-22
KR20120093932A (ko) 2012-08-23

Similar Documents

Publication Publication Date Title
US20130064788A1 (en) Il-17 family cytokine compositions and uses
JP7538721B2 (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
US20120269765A1 (en) Cytokine compositions and methods of use thereof
JP6883591B2 (ja) 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用
KR20080022539A (ko) 키메라 단백질
KR102321861B1 (ko) Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도
WO2012103240A2 (en) Receptor binding agents
RU2478645C2 (ru) Растворимый мутант рецептора фактора некроза опухоли
JP7751581B2 (ja) Ｉｌ－３７融合タンパク質及びその使用
JP5081277B2 (ja) ＩＬ−１ゼータ、ＩＬ−１ゼータスプライス変異体およびＸｒｅｃ２のＤＮＡおよびポリペプチド
EP2319929A1 (en) IL-1 related polypeptides
JP2002533122A5 (2)
JP4623342B2 (ja) Ｉｌ−１エータのｄｎａ及びポリペプチド
US20140105855A1 (en) Structural based design of il-17 dominant negative mutants
JP6930778B2 (ja) 抗ヒトインターロイキン１７ａモノクローナル抗体およびその使用
WO2026036390A1 (zh) 白介素12突变体及其用途
Fields The Molecular Basis of Il-1 Family Signaling: Strategies to Modulate Inflammation
Cao et al. Characterization of monoclonal antibodies against goat interleukin-18 and their application in the measurement of goat interleukin-18 in LPS-stimulated peripheral blood mononuclear cells by sandwich ELISA
EA046350B1 (ru) Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161013